One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Harmony Biosciences just hit that mark, with a jump from 70 to 81 Tuesday.
IBD's unique RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Harmony Biosciences is building a consolidation with a 41.61 buy point. See if it can break out in heavy volume.
Earnings grew 48% last quarter, up from 6% in the prior report. Revenue also increased, from 16% to 20%.
Harmony Biosciences holds the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Krystal Biotech are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
